Iodine for COVID-19: real-time analysis

Download Image

Post

c19early.org

Iodine for COVID-19

1 study with 141 patients

Serious outcome risk

Iodine

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Iodine studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−10%

Mortality (1)−10%

RCTs (1)−10%

Late (1)−10%

00.511.5+

← Iodine
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Recent:

Traksel.


Feb 2	Traksel et al., PLOS One, doi:10.1371/journal.pone.0341126	Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial
Feb 2	10% higher mortality (p=0.83), 34% lower ventilation (p=0.44), and 30% lower ICU admission (p=0.46). RCT 141 hospitalized COVID-19 patients showing no significant difference in mortality or ICU admission with 12.5 mg daily oral iodine for 8 days. Exploratory analysis found patients receiving iodine had significantly shorter ICU stays.